Ocular Therapeutix (NASDAQ: OCUL) is one of 88 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its peers? We will compare Ocular Therapeutix to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.

Profitability

This table compares Ocular Therapeutix and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocular Therapeutix -3,005.52% -101.03% -69.76%
Ocular Therapeutix Competitors -128.40% -34.43% -11.58%

Earnings and Valuation

This table compares Ocular Therapeutix and its peers gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Ocular Therapeutix $1.89 million -$44.70 million -2.70
Ocular Therapeutix Competitors $1.08 billion $133.13 million 101.40

Ocular Therapeutix’s peers have higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

53.3% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 26.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 11.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Ocular Therapeutix and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix 0 2 5 0 2.71
Ocular Therapeutix Competitors 181 1173 2553 90 2.64

Ocular Therapeutix presently has a consensus target price of $22.29, suggesting a potential upside of 288.93%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.70%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than its peers.

Risk & Volatility

Ocular Therapeutix has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Ocular Therapeutix’s peers have a beta of 1.16, suggesting that their average share price is 16% more volatile than the S&P 500.

Summary

Ocular Therapeutix peers beat Ocular Therapeutix on 7 of the 12 factors compared.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.